**In the claims:**

28. **(Withdrawn)** A method of enhancing the therapeutic treatment of an animal, including a human, for a pathological or injured or abnormal condition or for precautionary or preventative treatment before during or after a traumatic event or immuno compromised or vulnerable condition of the animal, by reducing the incidence or severity of side effect associated with a primary chemical treatment involving the administration of a primary substance, the method comprising administering to the animal, in conjunction with the administration of the primary treatment substance, a pharmacologically or therapeutically effective amount of a secondary substance to reduce the incidence or severity of the side effects, the secondary substance including an extract from cereal plants, the extract comprising a pharmaceutically acceptable extract derived from juice of cereal plants, the extract being carried in a pharmaceutically acceptable base carrier or excipient enabling the secondary substance to be taken up by the animal being treated, the secondary substance administered being in a quantity and over a period of time to be effective to achieve the side effect reduction.

29 **(Withdrawn)** A method as claimed in claim 28 wherein the juice is derived from rye grass (Secale Cereale).

30. **(Withdrawn)** A method as claimed in claim 28 wherein the extract is obtained from juice derived from the green leafy parts of the plants harvested when the plants are at the unjointed or immature development stage.

31. **(Withdrawn)** A method as claimed in claim 28 wherein the liquid extract comprises substantially only the water soluble components of the juice.

32. **(Withdrawn)** A method as claimed in claim 28 wherein the administration of the secondary substance occurs at least simultaneously with the administration of the primary treatment substance.

33. **(Withdrawn)** A method as claimed in claim 28 wherein the administration of the secondary substance comprises external application to the animal of the secondary substance so that the secondary substance is taken up by the body by absorption through the skin or mucous tissues.

34. **(Withdrawn)** A method as claimed in claim 33 wherein the secondary substance is administered sub-lingually by administering the secondary substance orally to be held in the mouth and under the tongue.

35. **(Withdrawn)** A method as claimed claim 28 wherein the primary substance comprises an antibiotic substance.

36 **(Withdrawn)** A method as claimed in claim 35 wherein the animal comprises a human being treated for chronic fatigue syndrome by the administration of the antibiotic substance.

37 **(Withdrawn)** A method as claimed in claim 35 wherein the animal is a human undergoing treatment by the administration of the antibiotic substance pre or post surgical procedure or intrusive examination.

38. **(Currently Amended)** A composition ~~adapted for~~ operative to treat an animal having a condition selected from a pathological condition, an

injured condition, an abnormal condition, and an immuno compromised condition, the composition comprising: ~~the treatment of an animal, comprising:~~

(A) a primary substance ~~adapted to~~ operative to treat ~~provide a primary chemical treatment of the~~ said condition of the animal, said primary substance causing the animal to present with at least one side effect;

(B) a secondary substance ~~adapted to~~ operative to reduce the incidence or severity of at least one of said side effects associated with said primary substance, wherein said secondary substance is a pharmaceutically acceptable liquid extract from a juice derived from cereal plants; and

(C) a carrier or excipient being pharmaceutically acceptable for application to and take up of said primary substance and said secondary substance by the animal.

39. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said primary substance is an antibiotic.

40. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said cereal plants are selected from the group consisting of rye grass (Secale Cereale), barley, wheat, corn, rice, oats, maize, sorghum, and millet.

41. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said cereal plant is rye grass (Secale Cereale).

42. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said cereal plants include leafy parts from which said juice is derived.

43. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said carrier is selected from the group consisting of water, cream, lotion, oil, gel, and powder.

44. **(Previously presented)** A pharmaceutical composition according to claim 43 wherein said cream is a vanishing cream adapted for topical or external application.

45. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said carrier is benzyl alcohol.

46. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said carrier is adapted for intravenous application to and take up by the animal.

47. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said carrier is adapted for ingestion by the animal.

48. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said carrier includes an anti-microbial agent.

49. **(Previously presented)** A pharmaceutical composition according to claim 48 wherein said anti-microbial agent is selected from the group consisting of an anti-bacterial agent, an anti-fungal agent, and an anti-yeast agent.

50. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said carrier includes an anti-bacterial agent.

51. **(Previously presented)** A pharmaceutical composition according to claim 38 wherein said liquid extract is primarily composed of water soluble components of said juice.

52. **(Currently amended)** A pharmaceutical composition administered to an animal before, during or after surgery that is operative to reduce the occurrence or severity of associated infections resulting therefrom, comprising:

(A) an antibiotic operative as ~~adapted to provide a~~ primary chemical treatment to treat said infections of ~~an~~ the animal undergoing surgery, said antibiotic causing a plurality of side effects to the animal;

(B) a pharmaceutically acceptable liquid extract from a juice derived from a cereal plant adapted to reduce the incidence or severity of said side effects associated with said antibiotic; and

(C) a pharmaceutically acceptable carrier.

53. **(Previously presented)** A pharmaceutical composition according to claim 52 wherein said cereal plant is selected from the group consisting of rye grass, barley, wheat, corn, rice, oats, maize, sorghum, and millet.

54. **(Previously presented)** A pharmaceutical composition according to claim 52 wherein said carrier is selected from the group consisting of water, cream, lotion, oil, gel, and powder.

55. **(Previously presented)** A pharmaceutical composition according to claim 52 wherein said carrier is adapted for intravenous application to and take up by the animal.

56. **(Previously presented)** A pharmaceutical composition according to claim 52 wherein said carrier is adapted for ingestion by the animal.

57. **(Previously presented)** A pharmaceutical composition according to claim 52 wherein said carrier includes an anti-microbial agent.

58. **(Previously presented)** A pharmaceutical composition according to claim 57 wherein said anti-microbial agent is an anti-bacterial agent.

60. **(Currently amended)** A pharmaceutical composition operative for the treatment of a human presenting with chronic fatigue syndrome, comprising: ~~an animal comprising a mixture including~~

(a) an antibiotic operative to treat chronic fatigue syndrome, said antibiotic associated with at least one side effect;

(b) a liquid extract derived from rye grass (Secale Cereale) juice and operative to alleviate at least one of said side effects;~~,~~ and

(c) a pharmaceutically acceptable carrier wherein said carrier includes an anti-microbial agent selected from the group consisting of an anti-bacterial agent, an anti-fungal agent, and an anti-yeast agent.

61. – 64. Cancelled.